Review: Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia
暂无分享,去创建一个
[1] M. Hongo,et al. A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease , 2008, Journal of Gastroenterology.
[2] T. Hershcovici,et al. Functional heartburn vs. non‐erosive reflux disease: similarities and differences , 2008, Alimentary pharmacology & therapeutics.
[3] W. Chey,et al. The influence of co‐morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro‐oesophageal reflux disease , 2008, Alimentary pharmacology & therapeutics.
[4] B. Naliboff,et al. The effect of auditory stress on perception of intraesophageal acid in patients with gastroesophageal reflux disease. , 2008, Gastroenterology.
[5] Q. Aziz,et al. Visceral hypersensitivity in non-erosive reflux disease , 2007, Gut.
[6] S. Quan,et al. Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease. , 2007, Gastroenterology.
[7] R. Holloway,et al. Defective triggering of secondary peristalsis in patients with non‐erosive reflux disease , 2007, Journal of gastroenterology and hepatology.
[8] D. Sifrim,et al. Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus , 2007, Gut.
[9] M. Hongo,et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non‐erosive and erosive gastro‐oesophageal reflux disease: a multicenter study from Japan , 2007, Alimentary pharmacology & therapeutics.
[10] N. Vakil,et al. Review article: the role of surgery in gastro‐oesophageal reflux disease , 2007, Alimentary pharmacology & therapeutics.
[11] V. Wong,et al. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] Y. Kinoshita,et al. A comparative study of intragastric acidity during post‐breakfast and pre‐dinner administration of low‐dose proton pump inhibitors: a randomized three‐way crossover study , 2006, Alimentary pharmacology & therapeutics.
[13] J. Dent,et al. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus , 2006, The American Journal of Gastroenterology.
[14] K. Haruma,et al. The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan , 2006, Journal of Gastroenterology.
[15] J. Inadomi,et al. Sub‐optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro‐oesophageal reflux disease , 2006, Alimentary pharmacology & therapeutics.
[16] A. Sonnenberg,et al. The Long-Term Natural History of Gastroesophageal Reflux Disease , 2006, Journal of clinical gastroenterology.
[17] Myung-Gyu Choi,et al. The Effect of Mosapride on Esophageal Motility and Bolus Transit in Asymptomatic Volunteers , 2006, Journal of clinical gastroenterology.
[18] B. Wong,et al. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[19] R. Knill-Jones,et al. Upper gastrointestinal mucosal abnormalities and blood loss complicating low‐dose aspirin and antithrombotic therapy , 2006, Alimentary pharmacology & therapeutics.
[20] J. Tack,et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double‐blind, placebo‐controlled study , 2006, Alimentary pharmacology & therapeutics.
[21] R. Fass,et al. Systematic review: proton‐pump inhibitor failure in gastro‐oesophageal reflux disease – where next? , 2005, Alimentary pharmacology & therapeutics.
[22] K. Lauritsen,et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study , 2005, Alimentary pharmacology & therapeutics.
[23] Y. Kinoshita,et al. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese , 2005, Scandinavian journal of gastroenterology.
[24] Y. Kinoshita,et al. Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists , 2004, Alimentary pharmacology & therapeutics.
[25] S. Ishihara,et al. Administration of H2 receptor antagonist with proton pump inhibitor is effective for long-term control of refractory reflux esophagitis. , 2004, Journal of clinical gastroenterology.
[26] J. Tack,et al. Approaches to endoscopic‐negative reflux disease: part of the GERD spectrum or a unique acid‐related disorder? , 2004, Alimentary pharmacology & therapeutics.
[27] C. Finizia,et al. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease , 2003, European journal of gastroenterology & hepatology.
[28] M. A. Karim Rumi,et al. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens , 2003, Journal of Gastroenterology.
[29] Y. Kinoshita,et al. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection , 2003, Journal of gastroenterology and hepatology.
[30] T. Koike,et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism , 2003, Alimentary pharmacology & therapeutics.
[31] D. Johnson,et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis , 2002, American Journal of Gastroenterology.
[32] Y. Kinoshita,et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis , 2001, Journal of gastroenterology and hepatology.
[33] S. Ishihara,et al. Influence of Helicobacter pylori infection on the prevalence of reflux esophagitis in Japanese patients , 2001, Journal of gastroenterology and hepatology.
[34] M. Onda,et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations , 2001, Journal of Gastroenterology.
[35] S. Ishihara,et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole , 2000, Alimentary pharmacology & therapeutics.
[36] D. Castell,et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal , 2000, Alimentary pharmacology & therapeutics.
[37] Y. Kinoshita,et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough , 2000, Alimentary pharmacology & therapeutics.
[38] I. Wiklund,et al. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. , 2000, European journal of gastroenterology & hepatology.
[39] Y. Horie,et al. Interaction Between NSAIDs and Steroid in Rat Stomach , 2000, Digestive Diseases and Sciences.
[40] S. Ishihara,et al. Prevalence of non‐ulcer dyspepsia in the Japanese population , 1999, Journal of gastroenterology and hepatology.
[41] O. Kawamura,et al. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings , 1999, Journal of Gastroenterology.
[42] J. Galmiche,et al. Functional esophageal disorders. , 1999, Gastroenterology.
[43] M. Matsuura,et al. Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis? , 1999, Journal of Gastroenterology.
[44] A. Blum,et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification , 1999, Gut.
[45] J. Hunter,et al. NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus? , 1999, Journal of clinical gastroenterology.
[46] O. Kawamura,et al. Interobserver and intraobserver variation in endoscopic assessment of GERD using the "Los Angeles" classification. , 1999, Gastrointestinal endoscopy.
[47] T Ishizaki,et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. , 1998, Clinical pharmacology and therapeutics.
[48] V. Savarino,et al. Effect of One-Month Treatment with Nonsteroidal Antiinflammatory Drugs (NSAIDs) on Gastric pH of Rheumatoid Arthritis Patients , 1998, Digestive Diseases and Sciences.
[49] Ruth,et al. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro‐oesophageal reflux disease , 1998, Alimentary pharmacology & therapeutics.
[50] L. Lundell,et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. , 1997, Scandinavian journal of gastroenterology.
[51] T. Chiba,et al. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese , 1997, Gut.
[52] J. Carson,et al. Dilated intercellular spaces: a morphological feature of acid reflux--damaged human esophageal epithelium. , 1996, Gastroenterology.
[53] M. Aldersley,et al. Patterns of acid reflux in complicated oesophagitis. , 1987, Gut.
[54] D. De Wolf,et al. Influence of xanthines on gastroesophageal reflux in infants at risk for sudden infant death syndrome. , 1986, Pediatrics.
[55] R. Buice,et al. Nifedipine: a potent inhibitor of contractions in the body of the human esophagus. Studies in healthy volunteers and patients with the nutcracker esophagus. , 1985 .
[56] T. Ekström,et al. Influence of theophylline on gastro-oesophageal reflux and asthma , 2004, European Journal of Clinical Pharmacology.
[57] N. Vakil,et al. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. , 2003, The American journal of medicine.
[58] Ebra,et al. ESOPHAGITIS ASSOCIATED WITH THE USE OF ALENDRONATE , 2000 .